Trident Lifeline partners with National Institutes of Pharmaceutical Education and Research- Ahmedabad

06 Mar 2025 Evaluate

Trident Lifeline has entered into a strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) regarding the technology transfer of Vorinostat- one of the crucial medications for treating Cutaneous T-Cell Lymphoma (CTCL), a rare blood originated skin cancer which is currently unavailable in India. This collaboration aims to revolutionize the treatment landscape for CTCL patients by providing access to a high-quality, domestically produced Vorinostat.

The company will scale up the production of Vorinostat and introduce it to the Indian market by leveraging NIPER Ahmedabad's expertise. Furthermore, as a part of CSR initiative, the company aims to provide Vorinostat free of charge to economically disadvantaged patients.

Trident Lifeline is engaged in the pharmaceutical business ethical marketing in domestic as well as international market.


Trident Lifeline Share Price

260.50 0.00 (0.00%)
26-Mar-2025 12:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...